StreetInsider.com News Articles

Eikon Therapeutics names new chief scientific officer from Bristol Myers Squibb

Thu, 03 Sep 2026 07:30:42 -0400

Eikon Therapeutics, Inc. (Nasdaq: EIKN) has appointed Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer, the company announced in a press release.

Dr. Chang joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President and Head of Cardiovascular Discovery Biology and Translational Pharmacology. Before that role, he served as Head of Cardiovascular Research at Gilead Sciences and then as Vice President of Disease Biology at MyoKardia, where he worked on the characterization of mavacamten, a drug later approved for the treatment of hypertrophic cardiomyopathy.

Dr. Chang also held academic positions at Stanford University, where

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Thu, 03 Sep 2026 07:30:00 -0400

MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer.

Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicine, foundational research, and drug discovery. He joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology.

“CP

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Thu, 03 Sep 2026 07:30:00 -0400

“CP

Eikon Therapeutics to Participate in Investor Conferences in September 2026

Wed, 26 Aug 2026 07:30:00 -0400

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:

Event:12^th Annual Cantor Global Healthcare Conference
Location: New York, NY
Date & Time: September 10, 2026 at 2:10 pm ET
Format: Fireside Chat

Event: The Morgan Stanley 24th Annual Global Healthcare Conference
Location: New

Eikon Therapeutics to Participate in Investor Conferences in September 2026

Wed, 26 Aug 2026 07:30:00 -0400

Event:12^th Annual Cantor Global Healthcare Conference
Location: New York, NY
Date & Time: September 10, 2026 at 2:10 pm ET
Format: Fireside Chat

Event: The Morgan Stanley 24th Annual Global Healthcare Conference
Location: New

Eikon Therapeutics (EIKN) Reiterated at Overweight by Cantor Fitzgerald

Fri, 21 Aug 2026 08:29:05 -0400

Cantor Fitzgerald analyst Imogen Mansfield reiterated an Overweight rating on Eikon Therapeutics Inc. (NASDAQ: EIKN).

The analyst commented, "EIKN is pursuing combinations for EIK1003 paclitaxel, carboplatin/ paclitaxel (both in multiple solid tumors), and abiraterone (in metastatic prostate cancer). EIK1004, EIKN's brain penetrant program, has monotherapy data upcoming at ESMO but EIKN plans to pursue a similar broad combination strategy. This asset has a particularly interesting opportunity in breast cancer, where BRCA mutant disease is at high risk of metastasizing to the brain."

For an analyst ratings summary and ratings history on Eikon Therapeutics Inc. click here. For more ratings news on

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald